Your search for non small cell lung cancer returned 10 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Mpr-drug-news remove
Mital Patel, PharmD remove
Drugs in the Pipeline remove

Your search for non small cell lung cancer returned 10 results

Sort Results:

Relevant Recent
Drugs in the Pipeline

sBLA Submitted for Additional Keytruda Indication

Merck announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA for Keytruda (pembrolizumab) for the treatment of advanced non-small cell lung cancer (NSCLC).
Drugs in the Pipeline

Melanoma Treatment Under Review for Preventing, Delaying Recurrence

The Food and Drug Administration (FDA) has accepted for filing and review the supplemental Biologics License Application (sBLA) for Yervoy (ipilimumab; Bristol-Myers Squibb) for the adjuvant treatment of patients with stage 3 melanoma who are at high risk of recurrence following complete surgical resection.
Drugs in the Pipeline

Entrectinib Designated Orphan Drug for NSCLC

The Food and Drug Administration (FDA) has granted Orphan Drug designation to entrectinib (Ignyta) for the treatment of TrkA-positive, TrkB-positive, TrkC-positive, ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC).
Drugs in the Pipeline

Non-Alcohol Formula of Docetaxel Injection Submitted for FDA Review

Teikoku Pharma USA announced that it has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for Docetaxel Injection Concentrate, Non-Alcohol Formula for the treatment of breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, and head and neck cancer.
Drugs in the Pipeline

Opdivo sBLA Under Priority Review for New Melanoma Indication

The Food and Drug Administration (FDA) has accepted for filing and has granted Priority Review to the supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) for the treatment of previously untreated patients with unresectable or metastatic melanoma.
Drugs in the Pipeline

Evofosfamide Fast Tracked for Advanced Pancreatic Cancer

The Food and Drug Administration (FDA) has granted Fast Track status to evofosfamide (Merck KGaA) in combination with gemcitabine, for the treatment of previously untreated patients with metastatic or locally advanced unresectable pancreatic cancer.
Drugs in the Pipeline

PD-L1 Positive NSCLC Therapy Designated Breakthrough Therapy

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to MPDL3280A (anti-PDL1 and RG7446; Genentech) for the treatment of patients with PD-L1 positive non-small cell lung cancer (NSCLC) whose disease has progressed during or after platinum-based chemotherapy.
Drugs in the Pipeline

Study on Opdivo for Renal Cell Carcinoma Halted Early

Bristol Myers Squibb Company announced that CheckMate-025, a Phase 3 study investigating Opdivo (nivolumab) vs. everolimus in previously treated patients with advanced or metastatic renal cell carcinoma (RCC) was stopped early due to the primary endpoint being met.
Drugs in the Pipeline

Entrectinib Designated Orphan Drug for Colorectal Cancer

The Food and Drug Administration (FDA) has granted Orphan Drug designation to entrectinib (Ignyta) for the treatment of TrkA-positive, TrkB-positive, TrkC-positive, ROS1-positive or ALK-positive colorectal cancer.